| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11274332 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| US11274331 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| US11268128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| US11060128 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
Jun, 2032
(8 years from now) | |
| US10793893 | CATALYST PHARMS | Methods of administering 3,4-diaminopyridine |
May, 2034
(10 years from now) | |
| US10626088 | CATALYST PHARMS | Determining degradation of 3,4-diaminopyridine |
Feb, 2037
(12 years from now) | |
Firdapse is owned by Catalyst Pharms.
Firdapse contains Amifampridine Phosphate.
Firdapse has a total of 6 drug patents out of which 0 drug patents have expired.
Firdapse was authorised for market use on 28 November, 2018.
Firdapse is available in tablet;oral dosage forms.
Firdapse can be used as method of treating lambert-eaton myasthenic syndrome with amifampridine.
Drug patent challenges can be filed against Firdapse from 28 November, 2022.
The generics of Firdapse are possible to be released after 25 February, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-223) | Nov 28, 2025 |
| New Patient Population(NPP) | Sep 29, 2025 |
| New Chemical Entity Exclusivity(NCE) | Nov 28, 2023 |
Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient
NCE-1 date: 28 November, 2022
Market Authorisation Date: 28 November, 2018
Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine
Dosage: TABLET;ORAL
FIRDAPSE family patents
